/
/
/

Gland Pharma Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-13%21%14%
-1%10%47%
--6%18%55%
14%11%9%11%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
GLAND
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,904.8₹456833 Cr37.7712.0762.82₹11479 Cr
9,188.5₹245426 Cr83.9134.04128.41₹2568 Cr
4,901.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,133.6₹113217 Cr25.099.4262.53₹5040 Cr
1,389.8₹112212 Cr33.299.7757.87₹3879 Cr
1,853₹101155 Cr92.526.829.25₹889 Cr
2,126.3₹97626 Cr17.6630.95154.36₹5333 Cr
2,351.8₹96859 Cr47.4213.7571.08₹1913 Cr
1,164.5₹96406 Cr29.925.3263.99₹4196 Cr
1,654.7₹93614 Cr25.2217.9596.84₹3505 Cr
2,926.3₹47920 Cr42.4519.2194.73₹1027 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020
₹1800 Cr₹1743 Cr₹1695 Cr₹1487 Cr₹1506 Cr₹1425 Cr₹1384 Cr₹1406 Cr₹1402 Cr₹1537 Cr₹1545 Cr₹1373 Cr₹1209 Cr₹785 Cr₹938 Cr₹1044 Cr₹857 Cr₹1103 Cr₹1063 Cr₹1080 Cr₹1154 Cr₹888 Cr₹859 Cr₹832 Cr₹884 Cr₹635 Cr
₹61 Cr₹111 Cr₹63 Cr₹84 Cr₹58 Cr₹44 Cr₹58 Cr₹60 Cr₹51 Cr₹42 Cr₹37 Cr₹53 Cr₹38 Cr₹39 Cr₹62 Cr₹66 Cr₹74 Cr₹65 Cr₹46 Cr₹51 Cr₹62 Cr₹47 Cr₹35 Cr₹20 Cr₹32 Cr₹46 Cr
₹1862 Cr₹1854 Cr₹1759 Cr₹1571 Cr₹1563 Cr₹1469 Cr₹1443 Cr₹1465 Cr₹1453 Cr₹1580 Cr₹1583 Cr₹1427 Cr₹1246 Cr₹824 Cr₹1000 Cr₹1110 Cr₹931 Cr₹1168 Cr₹1109 Cr₹1132 Cr₹1216 Cr₹935 Cr₹895 Cr₹852 Cr₹916 Cr₹681 Cr
₹1422 Cr₹1338 Cr₹1368 Cr₹1279 Cr₹1239 Cr₹1173 Cr₹1120 Cr₹1203 Cr₹1229 Cr₹1271 Cr₹1294 Cr₹1131 Cr₹980 Cr₹654 Cr₹686 Cr₹784 Cr₹622 Cr₹786 Cr₹742 Cr₹730 Cr₹743 Cr₹585 Cr₹620 Cr₹558 Cr₹496 Cr₹419 Cr
₹551 Cr₹624 Cr₹498 Cr₹398 Cr₹425 Cr₹392 Cr₹418 Cr₹357 Cr₹316 Cr₹401 Cr₹394 Cr₹377 Cr₹331 Cr₹207 Cr₹351 Cr₹362 Cr₹344 Cr₹414 Cr₹395 Cr₹428 Cr₹498 Cr₹375 Cr₹299 Cr₹318 Cr₹445 Cr₹286 Cr
₹4 Cr₹10 Cr₹4 Cr₹8 Cr₹11 Cr₹7 Cr₹23 Cr₹6 Cr₹6 Cr₹10 Cr₹5 Cr₹6 Cr₹5 Cr₹2 Cr₹3 Cr₹2 Cr₹90 L₹2 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹76 L₹47 L₹47 L
₹435 Cr₹506 Cr₹362 Cr₹284 Cr₹313 Cr₹288 Cr₹299 Cr₹257 Cr₹218 Cr₹298 Cr₹283 Cr₹290 Cr₹261 Cr₹111 Cr₹311 Cr₹324 Cr₹308 Cr₹380 Cr₹366 Cr₹401 Cr₹472 Cr₹349 Cr₹273 Cr₹293 Cr₹420 Cr₹262 Cr
₹317 Cr₹367 Cr₹261 Cr₹184 Cr₹215 Cr₹187 Cr₹205 Cr₹164 Cr₹144 Cr₹192 Cr₹192 Cr₹194 Cr₹194 Cr₹79 Cr₹232 Cr₹241 Cr₹229 Cr₹286 Cr₹273 Cr₹302 Cr₹351 Cr₹260 Cr₹204 Cr₹219 Cr₹314 Cr₹195 Cr

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
₹16 Cr₹16 Cr₹16 Cr₹16 Cr₹16 Cr₹16 Cr₹15 Cr
₹46 Cr₹5 L₹1 Cr₹2 Cr₹13 Cr₹25 Cr₹16 Cr
₹10296 Cr₹9134 Cr₹8706 Cr₹7941 Cr₹7128 Cr₹5861 Cr₹3614 Cr
₹10296 Cr₹9134 Cr₹8706 Cr₹7941 Cr₹7128 Cr₹5861 Cr₹3614 Cr
₹10358 Cr₹9151 Cr₹8724 Cr₹7959 Cr₹7158 Cr₹5903 Cr₹3646 Cr
₹70 Cr₹78 Cr₹107 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr
₹152 Cr₹163 Cr₹170 Cr₹84 Cr₹88 Cr₹74 Cr₹74 Cr
₹65 Cr₹71 Cr₹75 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr
₹196 Cr₹146 Cr₹137 Cr₹0₹0₹0₹0
₹482 Cr₹457 Cr₹489 Cr₹90 Cr₹94 Cr₹80 Cr₹81 Cr
₹834 Cr₹820 Cr₹768 Cr₹587 Cr₹463 Cr₹396 Cr₹249 Cr
₹658 Cr₹620 Cr₹520 Cr₹109 Cr₹76 Cr₹62 Cr₹82 Cr
₹117 Cr₹125 Cr₹111 Cr₹32 Cr₹43 Cr₹54 Cr₹28 Cr
₹1608 Cr₹1565 Cr₹1398 Cr₹729 Cr₹582 Cr₹513 Cr₹359 Cr
₹12449 Cr₹11173 Cr₹10611 Cr₹8778 Cr₹7834 Cr₹6496 Cr₹4086 Cr
₹10 Cr₹21 Cr₹16 Cr₹22 Cr₹13 Cr₹75 Cr₹12 Cr
₹243 Cr₹269 Cr₹320 Cr₹4 Cr₹4 Cr₹4 Cr₹5 Cr
₹6785 Cr₹5613 Cr₹5012 Cr₹2295 Cr₹2081 Cr₹1431 Cr₹1348 Cr
₹2292 Cr₹1466 Cr₹1065 Cr₹724 Cr₹579 Cr₹476 Cr₹380 Cr
₹4492 Cr₹4147 Cr₹3947 Cr₹1571 Cr₹1502 Cr₹954 Cr₹968 Cr
₹342 Cr₹151 Cr₹238 Cr₹177 Cr₹181 Cr₹338 Cr₹188 Cr
₹83 Cr₹88 Cr₹119 Cr₹129 Cr₹286 Cr₹78 Cr₹82 Cr
₹4 Cr₹4 Cr₹662 Cr₹0₹2 Cr₹2 Cr₹2 Cr
₹4922 Cr₹4390 Cr₹4966 Cr₹1877 Cr₹1982 Cr₹1372 Cr₹1240 Cr
₹0₹0₹0₹0₹155 Cr₹0₹0
₹1744 Cr₹1685 Cr₹1655 Cr₹1945 Cr₹1186 Cr₹1275 Cr₹756 Cr
₹1891 Cr₹1517 Cr₹1559 Cr₹871 Cr₹1075 Cr₹671 Cr₹602 Cr
₹3359 Cr₹2556 Cr₹1839 Cr₹3771 Cr₹3093 Cr₹3006 Cr₹1325 Cr
₹128 Cr₹150 Cr₹103 Cr₹91 Cr₹97 Cr₹84 Cr₹71 Cr
₹404 Cr₹875 Cr₹489 Cr₹222 Cr₹247 Cr₹88 Cr₹92 Cr
₹7527 Cr₹6783 Cr₹5645 Cr₹6901 Cr₹5852 Cr₹5124 Cr₹2846 Cr
₹5918 Cr₹5218 Cr₹4247 Cr₹6172 Cr₹5270 Cr₹4611 Cr₹2487 Cr
₹12449 Cr₹11173 Cr₹10611 Cr₹8778 Cr₹7834 Cr₹6496 Cr₹4086 Cr
₹626₹555₹530₹483₹435₹359₹234
₹626₹555₹530₹483₹435₹359₹234

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
₹1465 Cr₹1063 Cr₹1133 Cr₹1055 Cr₹1619 Cr₹1335 Cr₹993 Cr
₹277 Cr₹212 Cr₹224 Cr₹38 Cr-₹28 Cr₹17 Cr₹32 Cr
-₹254 Cr-₹6 Cr-₹53 Cr-₹418 Cr-₹393 Cr-₹436 Cr-₹80 Cr
₹1487 Cr₹1269 Cr₹1303 Cr₹675 Cr₹1197 Cr₹916 Cr₹945 Cr
₹1031 Cr₹915 Cr₹997 Cr₹364 Cr₹791 Cr₹605 Cr₹701 Cr
₹138 Cr₹1705 Cr-₹1757 Cr₹1208 Cr-₹1003 Cr-₹1524 Cr-₹766 Cr
-₹417 Cr-₹433 Cr-₹799 Cr₹15 Cr₹35 Cr₹1238 Cr-₹7 Cr
₹752 Cr₹2186 Cr-₹1560 Cr₹1587 Cr-₹177 Cr₹319 Cr-₹72 Cr
₹2556 Cr₹357 Cr₹1909 Cr₹319 Cr₹492 Cr₹169 Cr₹236 Cr
₹51 Cr₹13 Cr₹8 Cr₹3 Cr₹3 Cr₹4 Cr₹5 Cr
₹3359 Cr₹2556 Cr₹357 Cr₹1909 Cr₹319 Cr₹492 Cr₹169 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)2,915.00
Volume (₹)20.58 L
High (₹)2,940.90
Upper Circuit3,489.40
Low (₹)2,851.10
Lower Circuit2,326.40
Prev Close2,907.90
52W High (₹)3,039.80
Price2,928.20
52W Low (₹)1,573.60

Share Market Cap & Key Ratios Overview

M.Cap (₹)47920.30 Cr
Div. Yield (%)0.69
PE Ratio42.45
Debt to Equity0.02
Price to Book2.71
Book Value625.91
EPS (TTM)68.43
Face Value1.00
ROE (%)10.56

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
GLANDNSE
LTP
1W Low
1W High
Market cap (₹)
1904.8-15.2 (-0.79%)
1902
1984.80
4,56,833Cr
9181.5-57.5 (-0.62%)
9087
9467
2,45,426Cr
4900-150 (-2.97%)
4886.50
5066
1,87,320Cr
1133.8-57.2 (-4.80%)
1125.10
1187
1,13,217Cr
1390.4-33.1 (-2.33%)
1376.70
1426.10
1,12,212Cr
1852.2-86.3 (-4.45%)
1811.70
1949
1,01,155Cr
2124.4-47.1 (-2.17%)
2118.10
2192
97,626Cr
2350.7-32.2 (-1.35%)
2341.20
2419.20
96,859Cr
1163.9-14.1 (-1.20%)
1154.40
1179.90
96,406Cr
1653.5+8.2 (0.50%)
1622.60
1717
93,614Cr
2928.2+40.2 (1.39%)
2803
2948
47,920Cr

Gland Pharma Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹550.6Cr; with other income of ₹61.23Cr, profit before interest and tax came to ₹439.34Cr. Interest expense was ₹4.36Cr; PBT before exceptional items stood at ₹434.98Cr. Cost mix (full year): raw materials ₹2246.35Cr; employee cost ₹1628.84Cr; depreciation ₹111.26Cr; other expenses ₹1310.9Cr. Basis: consolidated annual results.

Gland Pharma Ltd Quaterly Results Key Takeaways

Gland Pharma Ltd reported ₹1800.27Cr total income from operations in Jun 2026, softer than ₹1742.79Cr in Mar 2026 but higher than ₹1505.62Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹550.6Cr; with other income of ₹61.23Cr, profit before interest and tax came to ₹439.34Cr. Interest expense was ₹4.36Cr, taking profit before tax to ₹434.98Cr. After tax of ₹118.02Cr, profit after tax stood at ₹316.96Cr (vs ₹366.68Cr in Mar 2026 and ₹215.48Cr in Jun 2025).